Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SCD1 inhibitor-3 (ML-270) is a highly effective and orally available compound that inhibits SCD1 with remarkable safety. SCD1 inhibitor-3 demonstrates strong potential for research in metabolic diseases, including obesity, type II diabetes, and dyslipidemia, as well as various skin conditions like acne and cancer.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 19,500 | |||
5 mg | 在庫あり | ¥ 45,500 | |||
10 mg | 在庫あり | ¥ 72,000 | |||
25 mg | 在庫あり | ¥ 122,500 | |||
50 mg | 在庫あり | ¥ 176,500 | |||
100 mg | 在庫あり | ¥ 248,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 49,500 |
説明 | SCD1 inhibitor-3 (ML-270) is a highly effective and orally available compound that inhibits SCD1 with remarkable safety. SCD1 inhibitor-3 demonstrates strong potential for research in metabolic diseases, including obesity, type II diabetes, and dyslipidemia, as well as various skin conditions like acne and cancer. |
In vivo | SCD1 inhibitor-3 (compound 17a), administered orally at a dosage of 5 mg/kg for 4 hours, effectively decreases the plasma C16:1/C16:0 triglycerides desaturation index by 54% in Lewis rats [1]. Furthermore, a dose-responsive reduction in the plasma triglycerides desaturation index is observed when the dosage ranges from 2 to 10 mg/kg, under the same conditions, indicating a dose-dependent efficacy [1]. |
別名 | SCD1-IN-3, SCD1 inhibitor-3, SCD1 inhibitor 17a |
分子量 | 393.37 |
分子式 | C19H16FN7O2 |
CAS No. | 1282606-48-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 35 mg/mL (89 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SCD1 inhibitor-3 1282606-48-7 Metabolism Dehydrogenase SCD1-IN-3 SCD1 inhibitor 17a Inhibitor inhibitor inhibit